ACR Convergence 2024

November 14-19, 2024. Washington, DC.

View by Number View by Title View Sessions

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 0357

Evaluating Meaningful Within-Person Change Thresholds in PROMIS-Fatigue Scores from Three Phase 3 Clinical Trials of Sarilumab for Rheumatoid Arthritis Using Empirical Cumulative Distribution Function (eCDF) Curves
Abstract Number: 0449

Evaluating Premenstrual Dysphoric Disorder in Women with Rheumatoid Arthritis and Healthy Female Subjects
Abstract Number: 1449

Evaluating Spine Structural Damage on a Single CT in Patients with Ankylosing Spondylitis, and According to the Presence of Skin Psoriasis
Abstract Number: 0629

Evaluating the Concordance Between SRI4 and BICLA Using Placebo Data from Randomized Controlled Trials of Patients with Active Systemic Lupus Erythematosus
Abstract Number: 0200

Evaluating the Effectiveness of Educational Initiatives on Recruiting Underrepresented Participants into SLE Clinical Trials
Abstract Number: 1162

Evaluating the Efficacy of Rituximab in the Treatment of Refractory Adult Idiopathic Inflammatory Myositis Using Total Improvement Score: Data from a Real-World Multi-Centre Registry in the United Kingdom
Abstract Number: 0086

Evaluating the Efficacyof B Cell Targeting Drug Candidates Using a Humanized BAFF Transgenic SLE Mouse Model
Abstract Number: 2178

Evaluating the Non-Inferiority of Mycophenolate Mofetil Compared to Methotrexate in Treating Juvenile Localized Scleroderma
Abstract Number: 0454

Evaluating the Rate of Cervical Cancer Screening and HPV Vaccination in Women with Systemic Lupus Erythematosus Within a Large Urban Healthcare System
Abstract Number: 0537

Evaluating the Usage of Janus Kinase Inhibitors in Rheumatology and Its Impact on Cardiovascular Risk
Abstract Number: 0392

Evaluation for the Presence of Antibodies to Malondialdehyde-Acetaldehyde Adduct in Juvenile Idiopathic Arthritis and Its Subtypes
Abstract Number: 1147

Evaluation of Adverse Pregnancy Outcomes in Patients with Inflammatory Myopathies and Ro Positivity
Abstract Number: 0740

Evaluation of an Accelerated Physical Aging Phenotype in Newly Diagnosed Patients with Polymyalgia Rheumatica
Abstract Number: 0636

Evaluation of Clinical, Histological and Biomarker Response After Induction Treatment of Lupus Nephritis (LN)
Abstract Number: 2179

Evaluation of Diagnostic Concordance Between Telehealth Encounters and In-Person Follow-up Assessments in Pediatric Rheumatology

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].